NOA - Neuroonkologische Arbeitsgemeinschaft

Archiv Publikationen

2015
Strahlenther Onkol. 2015;191: 461 - 469

Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: Local tumour control and survival.

2015
Eur J Cancer 2015;51: 382 - 390

Differently regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.

2014
Neuro Oncology 2014;16: 1630 - 1638

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promotor methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

2014
Nat Rev Neurol. 2014;10: 372 - 385

MGMT testing-the challenges for biomarker-based glioma treatment.

2014
Acta Neuropathol 2014;128: 561 - 571

Integrated DNA methylation and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic glioma.

2013
Acta Neuropathol. 2013;126: 907 - 915

Distribution of TERT promotor mutations in pediatric and adult tumors of the nervous system.

2013
Neurology 2013;81: 1515 - 1522

Prognostic or predictive value of MGMT promotor methylation in gliomas depends on IDH1 mutation.

2013
Front Oncol. 2013;3: 104

(18) F]FET-PET Imaging for treatment and response monitoring of radiation therapy in malignant glioma patients – a review.

2013
Acta Neuropathol. 2013;126: 443 - 451

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors wit better prognosis.

2013
Neuro Oncol. 2013;15:1017 - 1026

Malignant astrocytoms of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

2012
Expert Rev Anitcancer Ther. 2012;12: 623 - 633

Pathogenesis and management of primary CNS lymphoma.

2012
Ann Oncol. 2012;23: 2374 - 2380

Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial.